Fosfomycin-containing second-line treatment for helicobacter pylori infection

American Journal of Gastroenterology

Volumn 108, Issue 5, 2013, Pages 858-859

  Barahona Garrido, Josué ^a,b   Quiñonez, Nery F ^c   Cerda Contreras, Eduardo ^d   Maria Sarti, Helga ^e   Téllez Ávila, Félix I ^f  

^a Enfermedades Digestivas de Guatemala   (Guatemala)

^b Unit of Gastroenterology and Digestive Endoscopy   (Guatemala)

^c Instituto de Gastroenterología   (Guatemala)

^d Hospital Medica Sur   (Mexico)

^e Dermo Patolog í A Clinic   (Guatemala)

^f INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH SALICYLATE; CLARITHROMYCIN; ESOMEPRAZOLE; FOSFOMYCIN; LEVOFLOXACIN; METRONIDAZOLE; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIFUNGAL RESISTANCE; BACTERIAL STRAIN; BACTERIUM CULTURE; DRUG EFFICACY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IN VITRO STUDY; LETTER; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FOSFOMYCIN; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; TREATMENT OUTCOME;

EID: 84877310681     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2013.48     Document Type: Letter

References (14)

1. Wu W, Yang Y, Sun G . Recent insights into antibiotic resistance in Helicobacter pylori eradication . Gastroenterol Res Pract 2012; 2012: 723183.
2. Quinonez NF . Susceptibilidad in vitro de Helicobacter pylori como gu i a en el tratamiento de erradicaci o n . Revista Gastroavances 2009; 2: 2-4.
3. Barahona-Garrido J, Ortiz JC, Sarti HM et al. Pantoprazol, levofl oxacina y amoxicilina como tratamiento de primera l i nea para la erradicaci o n de Helicobacter pylori en Guatemala: efectividad en un pa i s en v i as de desarrollo. Endoscopia 2012; 24: 154-9.
4. Tursi A, Picchio M, Elisei W . Effi cacy and tolerability of a third-line, levofl oxacin-based, 10-day sequential therapy in curing resistant Helicobacter pylori infection . J Gastrointestin Liver Dis 2012; 21: 133-8.
5. Chuah SK, Hsu PI, Chang KC et al. Randomized comparison of two non-bismuthcontaining second-line rescue therapies for Helicobacter pylori . Helicobacter 2012; 17 : 216-23.
6. Mochizuki Tamayo H, Noriega Aldave AP. Anti microbial susceptibility of Helicobacter pylori to levofl oxacin determined in a miniwell format and disk diff usion tests using egg yolk agar . Rev Gastroenterol Peru 2011; 31 : 224-9.
7. Chuah SK, Tai WC, Hsu PI et al. The effi cacy of second-line anti-helicobacter pylori therapy using an extended 14-Day levofl oxacin/amoxicillin/proton-pump inhibitor treatment-A Pilot Study . Helicobacter 2012; 17: 374-81.
8. Cuadrado-Lavin A, Salcines-Caviedes JR, Carrascosa MF et al. Antimicrobial susceptibility of Helicobacter pylori to six antibiotics currently used in Spain . J Antimicrob Chemother 2012; 67: 170-3.
9. Megraud F, Coenen S, Versporten A et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption . Gut 2013; 62: 34-42.
10. Malfertheiner P, Megraud F, Morain CA et al., European Helicobacter Study Group. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut 2012; 61: 646-64.
11. Hunt RH, Xiao SD, Megraud F, et al., World Gastroenterology Organisation . Helicobacter pylori in developing countries . J Gastrointestin Liver Dis 2011; 20: 299-304.
12. Hendlin D, Stapley EO, Jackson M et al. Phosphonomycin, a new antibiotic produced by strains of Streptomyces . Science 1969; 166: 122-3.
13. Christensen BG, Leanza WJ, Beattie TR et al. Phosphonomycin: structure and synthesis. Science 1969; 166: 123-5.
14. Blacky A, Makristathis A, Apfalter P et al. In vitro activity of fosfomycin alone and in combination with amoxicillin, clarithromycin and metronidazole against Helicobacter pylori compared with combined clarithromycin and metronidazole . Eur J Clin Microbiol Infect Dis 2005; 24: 276-9.